Your browser is no longer supported. Please, upgrade your browser.
MYL Mylan N.V. daily Stock Chart
Mylan N.V.
IndexS&P 500 P/E141.07 EPS (ttm)0.12 Insider Own0.20% Shs Outstand516.40M Perf Week6.72%
Market Cap9.02B Forward P/E3.69 EPS next Y4.63 Insider Trans-1.09% Shs Float511.91M Perf Month-1.44%
Income62.60M PEG55.32 EPS next Q1.00 Inst Own89.20% Short Float4.49% Perf Quarter-0.70%
Sales11.62B P/S0.78 EPS this Y-95.00% Inst Trans1.99% Short Ratio2.94 Perf Half Y-6.72%
Book/sh21.81 P/B0.78 EPS next Y5.11% ROA0.20% Target Price22.07 Perf Year-0.81%
Cash/sh1.21 P/C14.06 EPS next 5Y2.55% ROE0.50% 52W Range12.75 - 23.11 Perf YTD-15.07%
Dividend- P/FCF4.67 EPS past 5Y-58.00% ROI2.30% 52W High-26.14% Beta1.55
Dividend %- Quick Ratio0.80 Sales past 5Y8.30% Gross Margin40.00% 52W Low33.88% ATR0.74
Employees35000 Current Ratio1.30 Sales Q/Q5.00% Oper. Margin7.40% RSI (14)57.48 Volatility4.30% 4.41%
OptionableYes Debt/Eq1.12 EPS Q/Q182.90% Profit Margin0.50% Rel Volume1.04 Prev Close17.25
ShortableYes LT Debt/Eq0.99 EarningsMay 11 BMO Payout0.00% Avg Volume7.80M Price17.07
Recom2.40 SMA204.13% SMA508.55% SMA200-7.59% Volume8,147,883 Change-1.04%
Jan-27-20Downgrade SVB Leerink Outperform → Mkt Perform $24
Jan-09-20Initiated Piper Sandler Neutral $21
Nov-07-19Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-05-19Downgrade CFRA Hold → Sell
Jul-19-19Initiated Wolfe Research Outperform
Jun-11-19Initiated Barclays Overweight $26
May-08-19Downgrade Wells Fargo Outperform → Market Perform $33 → $22
Mar-20-19Initiated SunTrust Buy $35
Mar-07-19Resumed UBS Neutral $31
Mar-06-19Upgrade Morgan Stanley Equal-Weight → Overweight $35
Feb-27-19Downgrade Bernstein Outperform → Mkt Perform $33
Jan-23-19Downgrade UBS Buy → Neutral
Nov-15-18Upgrade Argus Hold → Buy
Nov-06-18Upgrade BofA/Merrill Neutral → Buy
Oct-09-18Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-05-18Downgrade Mizuho Buy → Neutral
Aug-24-18Upgrade Evercore ISI In-line → Outperform
Aug-13-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Apr-12-18Upgrade Leerink Partners Mkt Perform → Outperform
Mar-15-18Reiterated Mizuho Buy $45 → $51
May-29-20 03:24PM  Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings PR Newswire
11:32AM  Here is How Hedge Funds Traded Mylan N.V. (MYL) Recently Insider Monkey
11:29AM  Statement Pursuant to Section 19(a) of the Investment Company Act of 1940: DEX Business Wire
May-26-20 08:00AM  Pfizer Is Charging Ahead With A Coronavirus Vaccine Is PFE Stock A Buy? Investor's Business Daily
May-22-20 09:13AM  Top Research Reports for Intel, Adobe & AMD Zacks
May-19-20 04:38PM  Delaware Enhanced Global Dividend and Income Fund Appoints Allan Saustrup Jensen as Co-Manager Business Wire
May-18-20 11:52AM  Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes; on review for downgrade Moody's +8.58%
May-17-20 02:03PM  Better Buy: Pfizer vs. Bristol Myers Squibb Motley Fool
May-14-20 10:08AM  Markets Set Out on Long Journey to Recovery: 4 ROE Picks Zacks
06:43AM  Coronavirus update: Global case tally tops 4.31 million as Russia sees spike in cases, Brazil and Mexico suffer deadliest day yet MarketWatch
May-13-20 12:23PM  Mylan to Present at the 2020 RBC Capital Markets' Virtual Global Healthcare Conference PR Newswire
08:33AM  US STOCKS-Futures climb ahead of Fed Chair Powell's address Reuters
07:40AM  The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter Benzinga
May-12-20 05:26PM  Gilead Strikes Deal With Mylan to Supply Remdesivir Internationally Motley Fool
04:16PM  Mylan to Supply Investigational Antiviral Remdesivir for the Potential Treatment of COVID-19 PR Newswire
02:55PM  Gilead announces non-U.S. deals with five generic drugmakers for remdesivir MarketWatch
11:50AM  Is Mylan (MYL) Stock Undervalued Right Now? Zacks
May-11-20 09:49PM  Edited Transcript of MYL earnings conference call or presentation 11-May-20 2:30pm GMT Thomson Reuters StreetEvents
05:30PM  Mylan N.V. (MYL) Q1 2020 Earnings Call Transcript Motley Fool
04:21PM  Drug Stockpiling Lends Generic Pharma Stock A Boost But Not Enough Investor's Business Daily
01:00PM  What's Behind Mylan's Mixed Q1 Results Motley Fool
10:53AM  Mylan (MYL) Beats on Q1 Earnings on Coronavirus-Led Stockpiling Zacks
10:09AM  Drug Stockpiling Lends Generic Pharma Stock A Boost But Not Enough Investor's Business Daily
09:45AM  Mylan (MYL) Q1 Earnings Top Estimates Zacks
09:32AM  Mylan Swings to Profit as Drug Sales Jump
08:57AM  Mylan Stock Needs More Base Building for a Sustained Turnaround
08:50AM  Mylan's stock gains 2%; guidance for 2020 reaffirmed MarketWatch
08:27AM  Mylan first-quarter revenue jumps 5% on drug stockpiling Reuters
08:15AM  Mylan Reports First Quarter 2020 Results and Reaffirms 2020 Guidance PR Newswire
May-10-20 10:26AM  Retail sales, Fed Chair Jerome Powell speaks: What to know in the week ahead Yahoo Finance
07:33AM  How Low Will Pfizer's Dividend Go After the Mylan-Upjohn Deal? Motley Fool
May-09-20 10:01PM  Revance Therapeutics (RVNC) Q1 2020 Earnings Call Transcript Motley Fool
May-08-20 08:59AM  Is a Surprise Coming for Mylan (MYL) This Earnings Season? Zacks
08:00AM  Mylan to Present at the BofA Securities Virtual Health Care Conference 2020 PR Newswire
May-07-20 01:57PM  Theravance (TBPH) Q1 Earnings Miss, Revenues Beat Estimates Zacks
May-04-20 03:40PM  Mylan N.V. (MYL): Were Hedge Funds Right About This Stock? Insider Monkey
01:06PM  Mylan Releases "A Legacy of Impact: 2019 Global Social Responsibility Report" PR Newswire
10:29AM  Mylan (MYL) to Report Q1 Earnings: Is a Beat in the Cards? Zacks
May-01-20 02:45PM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Sale of These Companies; Investors are Encouraged to Contact the Firm - FSB, MYL, TCO ACCESSWIRE
Apr-30-20 05:30PM  Lifshitz Law Firm, P.C. Announces Investigation of FGL Holdings (FG), Franklin Financial Network, Inc. (FSB), Mylan N.V. (MYL) and Willis Towers Watson Public Limited Company (WLTW) GlobeNewswire
Apr-28-20 07:00AM  Mylan and Biocon Launch Fulphila®, Biosimilar Pegfilgrastim, in Canada CNW Group
06:57AM  Pfizer profit down 12% as sales of off-patent drugs fall Reuters
Apr-24-20 10:49AM  Mylan to Release First Quarter 2020 Financial Results on May 11, 2020 PR Newswire
Apr-22-20 12:30PM  EU clears Mylan's purchase of Pfizer's Upjohn unit with conditions Reuters
Apr-21-20 01:47PM  Mylan Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Mylan N.V. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm PR Newswire
10:49AM  OPB, TERP, MYL, and FG SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers GlobeNewswire
Apr-17-20 12:10PM  Why Mylan (MYL) is Poised to Beat Earnings Estimates Again Zacks
Apr-15-20 06:34PM  Mylan's Robert Coury back as executive chairman Reuters -5.44%
06:29PM  Mylan's Robert Coury back as executive chairman Reuters
05:46PM  Mylan names Coury executive chairman again American City Business Journals
05:00PM  Mylan Board Appoints Robert J. Coury As Executive Chairman of Mylan N.V. PR Newswire
Apr-14-20 03:35PM  IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Mylan N.V. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - MYL ACCESSWIRE
01:35PM  MYLAN N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Merger ACCESSWIRE
12:45PM  Mylan Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Mylan N.V. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - MYL ACCESSWIRE
Apr-08-20 01:42PM  Mylan Updates Its Efforts Regarding COVID-19 PR Newswire +5.36%
Apr-07-20 09:45AM  Trumps personal stake in the malaria-drug maker Sanofi could be as small as $99 MarketWatch
Apr-05-20 10:22AM  Theres scant evidence so far for chloroquine as a COVID-19 drug but theres already a shortage MarketWatch
Apr-03-20 02:39AM  RPT-Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19 Reuters
02:36AM  Novartis, Incyte join repurposing wave to give Jakavi a trial run in COVID-19 Reuters
Apr-02-20 10:36AM  Novartis Terminates Sale of Sandoz Dermatology Business Zacks
Mar-31-20 08:57AM  How Much Are Mylan N.V. (NASDAQ:MYL) Insiders Spending On Buying Shares? Simply Wall St.
Mar-30-20 08:05AM  Mylan offers concessions to address EU concerns about Pfizer deal Reuters
Mar-29-20 11:49AM  Drug makers on shaky ground as clinical trials are postponed and drug launches delayed amid pandemic MarketWatch
Mar-28-20 11:30AM  Mylan (MYL) Down 20.3% Since Last Earnings Report: Can It Rebound? Zacks
Mar-27-20 06:45PM  Covid-19 Could Benefit Generic Drug Companies
01:20PM  Coronavirus Drugs Already in the Pipeline Kiplinger
09:30AM  Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept PR Newswire
09:10AM  Pfizer and Mylan Postpone Upjohn Deal. Analysts Arent Worried.
Mar-26-20 08:23AM  The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger Benzinga
07:22AM  Mylan delays merger with Upjohn due to COVID-19 pandemic American City Business Journals
07:01AM  Drugmakers Mylan, Pfizer delay merger due to coronavirus outbreak Reuters
06:45AM  Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn PR Newswire
06:45AM  Mylan and Pfizer Provide Update Regarding Proposed Combination of Mylan and Upjohn Business Wire
Mar-25-20 02:24PM  Mylan Says Indias Coronavirus Lockdown Wont Affect Drug Production
01:48PM  Mylan waives exclusive U.S. distribution rights for potential COVID-19 therapy Reuters
01:30PM  Mylan Announces Additional Efforts to Support Response to the COVID-19 Pandemic by Voluntarily Waiving its Marketing Exclusivity in the U.S. for Lopinavir/Ritonavir to Help Ensure Wider Availability to Meet Potential COVID-19 Patient Needs PR Newswire
11:20AM  Pfizer Inc. -- Moody's assigns A1 to Pfizer's notes, on review for downgrade Moody's
10:00AM  Pfizer Is Entering The Coronavirus Drug Hunt But Is PFE Stock A Buy? Investor's Business Daily
Mar-24-20 09:57AM  Companies Plan to Boost Production of Controversial Malaria Drug as Demand Jumps
Mar-22-20 10:13AM  Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness MarketWatch
Mar-21-20 11:03AM  Coronavirus update: 284,566 cases, 11,868 deaths, New York and Illinois in lockdown MarketWatch
10:23AM  Good news for the stock market would be any potential treatment against the coronavirus MarketWatch
Mar-20-20 09:51AM  Dow Jones Today, Stocks Edge Up; Coronavirus Stimulus Plans In Motion As California, Pennsylvania Lock Down Investor's Business Daily
09:11AM  CORRECTED-US STOCKS-Wall Street set for gains at end of blistering week Reuters
08:56AM  Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus Zacks
07:47AM  Teva to donate 6 million doses of hydroxychloroquine, floated as a potential treatment for COVID-19 MarketWatch
07:44AM  The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company Benzinga
06:27AM  Edited Transcript of MYL earnings conference call or presentation 27-Feb-20 9:30pm GMT Thomson Reuters StreetEvents
Mar-19-20 04:50PM  Mylan restarts production of potential COVID-19 treatment in West Virginia American City Business Journals
03:49PM  Mylan to restart production of hydroxychloroquine MarketWatch
03:25PM  Mylan Ramps Up U.S. Manufacturing of Hydroxychloroquine Sulfate Tablets to Meet Potential COVID-19 Patient Needs PR Newswire
02:56PM  Potential coronavirus treatment touted by Trump already in shortage -pharmacists Reuters
Mar-17-20 01:41PM  Mylan institutes work-from-home policy at its Southpointe office American City Business Journals
Mar-11-20 12:41PM  Do Hedge Funds Love Mylan N.V. (MYL)? Insider Monkey
10:00AM  Is Biogen Stock A Buy As It Takes Yet Another Run At Alzheimer's? Investor's Business Daily
Mar-10-20 12:59PM  Mylan Wins District Court Decision Against Sanofi's Lantus® SoloSTAR® Patent PR Newswire
08:00AM  Mylan Pharmaceuticals ULC Launches Wixela® Inhub® (fluticasone propionate and salmeterol inhalation powder, USP), the First Available Bioequivalent Alternative to ADVAIR® DISKUS® (fluticasone propionate and salmeterol inhalation powder) in Canada CNW Group
Mar-09-20 09:43AM  Mylan-Upjohn Merger in Focus, Coronavirus Might Hit Supply Zacks -6.62%
08:00AM  U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review PR Newswire
Mar-06-20 01:19PM  Pfizer Wont Win the Coronavirus Pharma War InvestorPlace
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Hatfield, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Malik RajivPresidentMar 03Option Exercise0.0043,3830283,195Mar 04 06:41 PM
BRESCH HEATHER MChief Executive OfficerMar 03Option Exercise0.0070,4960302,999Mar 04 06:38 PM
Parks Kenneth ScottChief Financial OfficerMar 03Option Exercise0.0013,945039,476Mar 04 06:33 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002200583Mar 04 06:32 PM
Campbell PaulSee RemarksMar 03Option Exercise0.002,906031,238Mar 04 06:32 PM
Mauro AnthonyChief Commercial OfficerMar 03Option Exercise0.0019,3670125,321Mar 04 06:31 PM
PARRISH MARK WDirectorMar 02Option Exercise0.006,011045,795Mar 04 06:48 PM
VANDERVEEN RANDALL LDirectorMar 02Option Exercise0.006,011050,217Mar 04 06:44 PM
Malik RajivPresidentMar 02Option Exercise0.0048,1610260,076Mar 04 06:41 PM
BRESCH HEATHER MChief Executive OfficerMar 02Option Exercise0.0073,2130264,089Mar 04 06:38 PM
van der Meer Mohr PaulineDirectorMar 02Option Exercise0.006,01108,695Mar 04 06:37 PM
Lyons Dillon JoEllenDirectorMar 02Option Exercise0.006,011018,039Mar 04 06:35 PM
MARK RICHARD ADirectorMar 02Option Exercise0.009,007013,007Mar 04 06:35 PM
KORMAN HARRYDirectorMar 02Option Exercise0.006,011028,945Mar 04 06:35 PM
Parks Kenneth ScottChief Financial OfficerMar 02Option Exercise0.0021,646034,082Mar 04 06:33 PM
Campbell PaulSee RemarksMar 02Option Exercise0.005510494Mar 04 06:32 PM
Campbell PaulSee RemarksMar 02Option Exercise0.006,109030,550Mar 04 06:32 PM
DIMICK NEIL FDirectorMar 02Option Exercise0.006,011053,017Mar 04 06:32 PM
Vollebregt Sjoerd SDirectorMar 02Option Exercise0.006,011048,269Mar 04 06:33 PM
HIGGINS MELINA EDirectorMar 02Option Exercise0.006,011039,131Mar 04 06:30 PM
Cindrich Robert JDirectorMar 02Option Exercise0.006,011027,479Mar 04 06:31 PM
Mauro AnthonyChief Commercial OfficerMar 02Option Exercise0.0021,6460115,119Mar 04 06:31 PM
Campbell PaulSee RemarksFeb 05Sale23.0011,611267,05325,413Feb 07 06:00 PM
HIGGINS MELINA EDirectorAug 15Buy17.6820,000353,54833,120Aug 19 07:29 PM
Vollebregt Sjoerd SDirectorAug 14Buy18.8124,000451,43942,258Aug 15 06:30 PM
Vollebregt Sjoerd SDirectorAug 13Buy19.1110,000191,10018,258Aug 15 06:30 PM
COURY ROBERT JDirectorAug 02Buy20.0649,8591,000,012947,194Aug 05 08:00 AM
MARK RICHARD ADirectorJul 31Buy20.974,00083,8744,000Aug 02 06:48 PM
COURY ROBERT JDirectorJun 24Option Exercise0.00750,00001,309,835Jun 25 08:04 PM